While there are many small molecule inhibitors of CDK1 and CDK2, none have reached FDA approval.48 There currently exists one ATP-competitive inhibitor of PLK1 approved for treatment of AML,49 and there is evidence to suggest the FDA approved proteosome inhibitor bortezomib and the approved anti-alcohol abuse drug Disulfiram both inhibit expression of PLK1.50,51 These and other PLK1 inhibitors currently in clinical trials should be considered in future studies for treatment of cancers with high AURK activity. The gene discussed is CDK2; the disease is acute myeloid leukemia.